This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

Nizatidine

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Nizatidine is an antihistamine that blocks H2 receptor activity.[1][2] Nizatidine is used to treat ulcers and gastroesophageal reflux disease (GERD), plus heartburn.[1][2]

Nizatidine is marketed under different brand names Axid AR, Axid Pulvules.[1][2]

Theory[edit | edit source]

Evidence[edit | edit source]

Some evidence exists from a small observational study of Long COVID patients by Glynne et al. (2022).[3]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Nizatidine is perscription only abd available as an oral capsule, tablet, or oral solution.[1][2]

Notable studies[edit | edit source]

  • 2022, Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines[3] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. Jump up to: 1.0 1.1 1.2 1.3 "Nizatidine Uses, Dosage & Side Effects". Drugs.com. Retrieved February 19, 2022.
  2. Jump up to: 2.0 2.1 2.2 2.3 "Nizatidine: Uses, Interactions, Mechanism of Action". Drugbank Online. Retrieved February 19, 2022.
  3. Jump up to: 3.0 3.1 Glynne, Paul; Tahmasebi, Natasha; Gant, Vanya; Gupta, Rajeev (January 2022). "Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines". Journal of Investigative Medicine. 70 (1): 61–67. doi:10.1136/jim-2021-002051. ISSN 1081-5589. PMC 8494538. PMID 34611034.